On Wednesday, GSK plc announced a significant settlement deal aimed at resolving about 80,000 Zantac product liability cases currently pending in U.S. state courts. These cases, which claim that the heartburn medication Zantac (ranitidine) is linked to cancer, account for approximately 93% of all lawsuits against the company related to this product. The total cost...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here